GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » China Resources Boya Bio-pharmaceutical Group Co Ltd (SZSE:300294) » Definitions » Selling, General, & Admin. Expense

China Resources Boya Bio-pharmaceutical Group Co (SZSE:300294) Selling, General, & Admin. Expense : ¥572 Mil (TTM As of Mar. 2024)


View and export this data going back to 2012. Start your Free Trial

What is China Resources Boya Bio-pharmaceutical Group Co Selling, General, & Admin. Expense?

Selling, general, & admin. expense (SGA) includes the direct and indirect costs and all general and administrative expenses of a company. China Resources Boya Bio-pharmaceutical Group Co's selling, general, & admin. expense for the three months ended in Mar. 2024 was ¥142 Mil. Its selling, general, & admin. expense for the trailing twelve months (TTM) ended in Mar. 2024 was ¥572 Mil.


China Resources Boya Bio-pharmaceutical Group Co Selling, General, & Admin. Expense Historical Data

The historical data trend for China Resources Boya Bio-pharmaceutical Group Co's Selling, General, & Admin. Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

China Resources Boya Bio-pharmaceutical Group Co Selling, General, & Admin. Expense Chart

China Resources Boya Bio-pharmaceutical Group Co Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Selling, General, & Admin. Expense
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1,024.10 925.12 829.72 763.91 633.09

China Resources Boya Bio-pharmaceutical Group Co Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Selling, General, & Admin. Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 203.19 141.56 269.36 18.98 141.99

Competitive Comparison of China Resources Boya Bio-pharmaceutical Group Co's Selling, General, & Admin. Expense

For the Biotechnology subindustry, China Resources Boya Bio-pharmaceutical Group Co's Selling, General, & Admin. Expense, along with its competitors' market caps and Selling, General, & Admin. Expense data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


China Resources Boya Bio-pharmaceutical Group Co's Selling, General, & Admin. Expense Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, China Resources Boya Bio-pharmaceutical Group Co's Selling, General, & Admin. Expense distribution charts can be found below:

* The bar in red indicates where China Resources Boya Bio-pharmaceutical Group Co's Selling, General, & Admin. Expense falls into.



China Resources Boya Bio-pharmaceutical Group Co Selling, General, & Admin. Expense Calculation

Selling, General, & Admin. Expense (SGA) includes the direct and indirect costs and all general and administrative expenses of a company. For instance, personnel cost, advertising, rent, communication costs are all part of SGA.

Selling, General, & Admin. Expense for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥572 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


China Resources Boya Bio-pharmaceutical Group Co  (SZSE:300294) Selling, General, & Admin. Expense Explanation

An efficient operation keeps SGA costs low and thus has higher profit margin. The percentage of SGA relative to total revenue is an indication of how efficiently the company operates. Compare this percentage among the companies in the same industry is a good way of finding more efficient operations. A comparison of the SGA cost relative to the revenue with the historical value can also be an indication of how efficient the company has become.

Warren Buffett likes companies with consistent SGA as the percentage of gross profit.

Companies with no durable competitive advantage show wild variation in SG&A as % of Gross Profit.

If SGA is less than 30% of Gross Profit, it is fantastic. If SGA is nearing 100%, it is is in highly competitive industry.


China Resources Boya Bio-pharmaceutical Group Co Selling, General, & Admin. Expense Related Terms

Thank you for viewing the detailed overview of China Resources Boya Bio-pharmaceutical Group Co's Selling, General, & Admin. Expense provided by GuruFocus.com. Please click on the following links to see related term pages.


China Resources Boya Bio-pharmaceutical Group Co (SZSE:300294) Business Description

Traded in Other Exchanges
N/A
Address
Number 333, Huiquan Road, High-tech Industrial Park, Jiangxi Province, Fuzhou, CHN, 344000
China Resources Boya Bio-pharmaceutical Group Co Ltd is a China-based medical industry group that integrates biochemical drugs, chemical drugs, and active pharmaceutical ingredients. It is engaged in the provision of medical and health products and services. The product categories of the company include blood products, biochemical drugs, chemical medicines and others. Some of the company's blood products include human albumin, rabies immunoglobulin, intravenous human immunoglobulin and human fibrinogen.

China Resources Boya Bio-pharmaceutical Group Co (SZSE:300294) Headlines

No Headlines